Hematopoietic stem cell transplantation autologous

Assess the role of autologous hematopoietic stem cell transplantation in relapsed Hodgkin s lymphoma and non-Hodgkin s lymphoma. [Pg.1371]

Salvage chemotherapy at conventional doses or high-dose chemotherapy and autologous hematopoietic stem cell transplantation... [Pg.718]

Patients who relapse after an initial complete response can be treated with the same regimen, a non-cross-resistant regimen, radiation therapy, or high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). [Pg.719]

Snowden J, Passweg J, Moore J, et al Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis a report from the EBMT and ABMTR. J Rheumatol 2004 31 482-488. [Pg.218]

Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007 40 549-555. [Pg.219]

Voltarelli J, Couri C, Stracieri A, et al Autologous nonmyeloablative hematopoietic stem cell transplantation 15 in newly diagnosed type 1 diabetes mellitus. JAMA 2007 297 1568-1576. [Pg.219]

Rituximab Induced Neutropenia After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma... [Pg.223]

Autologous hematopoietic stem cell transplantation (AHSCT) has undergone phase I/n trials for severe Crohn s disease (Craig et al., 2003). While clinical remission occurred as a result of AHSCT, some evidence of minor laboratory abnormalities and slight inflammation of the colon on colonoscopy w ere reported at the 1 year post transplant follow up. [Pg.291]

Autologous hematopoietic stem cell transplantation has undergone phase I/II trials for several autoimmune disorders. Aside from its invasive nature discuss the pros and cons for its use. [Pg.293]

Autologous hematopoietic stem cell transplantation (AHSCT) was evaluated in a group of MS patients with aggressive and advanced disease (Nash et al., 2003) with some promise but also wkh evidence that neurologic loss continued. One important hypothesis from that study was the discordant nature of inflammatory measures and functional deficits (Healey et al., 2004). [Pg.598]

Plasmapheresis is effective in patients with severe neuropsychiatric SLE refractory to conventional treatment. Intrathecal methotrexate and dexamethasone is also beneficial to those patients (Dong et al., 2001 Baca et al., 1999). Positive results of a phase I/II trial of autologous hematopoietic stem cell transplantation (AHSCT) at Northwestern University in Chicago, UL has led to a phase III ASCT trial. As with other similar trials involving autoimmune disease, the ASCT trial is designed to include standard of care IV pulse cyclophosphamide (Burt et al., 2003b). [Pg.289]

Perseghin P, Balduzzi A, Bonaiiomi S, Dassi M, Buscemi F, Longoni D, Rovelli A, Uderzo C. Infusion-related side-effects in children undergoing autologous hematopoietic stem cell transplantation for acute leukemia. Bone Marrow Transplant 2000 26(1) 116-18. [Pg.1132]

Herrmann, R.P. Leather, M. Leather, H.L. Leen, K. Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting. Oncol. Nurs. Forum 1998, 25, 1427-1432. [Pg.445]

Steingrimsdottir H. Gruber A. Bjorkholm M. et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000,85,832-838. [Pg.214]

Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988 71 723-727. [Pg.1804]

Many patients with Hodgkin s lymphoma will be refractory to initial therapy or will have a recurrence following a complete remission. Response to salvage therapy depends on the extent and site of recurrence, previous therapy, and duration of initial remission. High-dose chemotherapy and autologous hematopoietic stem cell transplantation should be considered in patients with refractory or relapsed disease. [Pg.2439]

Conventional-dose salvage therapy can induce responses in patients with aggressive lymphomas who relapse, but longterm survival and cure is uncommon. Some patients with aggressive lymphoma who relapse and respond to salvage therapy can be cured with high-dose chemotherapy and autologous hematopoietic stem cell transplantation. [Pg.2439]

Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin s lymphoma a multivariate cohort analysis. Blood 2003 102 2351-2357. [Pg.2556]

Cooper BW, Creger RJ, Soegiarso W, Mackay WL, Lazarus HM. Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic stem cell transplantation effect of aminoglycoside therapy. Am JMed 99y) 94, 497-504. [Pg.211]

Capizzi SA, Kumar S, Huneke NE, et al. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001 27(12) 1299-1303. [Pg.570]

Mossad S, Kalaycio M, Sobecks R, et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transplant 2005 35(4) 375 81. [Pg.570]

Anecdotal responses have been cited with cyclosporin A (206), monoclonal antibodies targeted against T cells (207,208) humanized anti-CD4 antibodies (18), alemtuzumab (CAMPATH-IH), a monoclonal antibody directed against CD52 (81,209), 15-deoxyspergualin (210,211), and etoposide (180,212), and autologous hematopoietic stem cell transplants (213), but data are limited to a few cases in uncontrolled trials. [Pg.628]

Autologous hematopoietic stem cell (HSC) transplantation, a standard treatment for hematological malignancies, such as non-Hodgkin s... [Pg.515]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...